ePT--the Electronic Newsletter of Pharmaceutical Technology
Billerica, MA (Apr. 13)-Millipore Corporation has become the first company to integrate radio frequency identification (RFID) technology with the filtration products used to manufacture biopharmaceutical drugs.
Billerica, MA (Apr. 13)-Millipore Corporation (www.millipore.com) has become the first company to integrate radio frequency identification (RFID) technology with the filtration products used to manufacture biopharmaceutical drugs.
The new technology, which Millipore has named "SMART" Technology, enables users to quickly retrieve information such as when and how the product was manufactured. When the filters are coupled with sensors, users can also access real-time information about product performance and identify any fluids that were present during the manufacturing process. The information will help ensure regulatory compliance and make recording and conveying manufacturing data faster and more reliable.
Although RFID has long been used by other industries, its use in the pharmaceutical industry has been slower, although there is increasing interest in the technology. RFID offers several benefits over previous labeling methods such as barcodes. Unlike barcodes, RFID does not require a line of site, allowing for nonlinear access to information. In addition, RFID technology is rewritable and encryptable, difficult to remove, mechanically and thermally stable, and gamma irradiatable.
Millipore will formally introduce its SMART Technology at this year’s INTERPHEX conference, which is being held April 24–26 in New York City.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.